Cargando…
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Pancreatic cancer is a lethal disease with poor prognosis. Gemcitabine has been the first line systemic treatment for pancreatic cancer. However, the rapid development of drug resistance has been a major hurdle in gemcitabine therapy leading to unsatisfactory patient outcomes. With the recent renewe...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554139/ https://www.ncbi.nlm.nih.gov/pubmed/28801576 http://dx.doi.org/10.1038/s41598-017-08436-6 |